Volume 21, Number 8—August 2015
Research
Risk for Mycobacterial Disease among Patients with Rheumatoid Arthritis, Taiwan, 2001–2011
Table 1
Variables | With RA, no. (%), n = 28,997† | Without RA, no. (%), n = 115,988† | p value |
---|---|---|---|
Age at entry, y‡ | |||
18–44 | 7,495 (25.9) | 29,980 (25.9) | 1.000 |
45–64 | 14,865 (51.3) | 59,460 (51.3) | |
>65 |
6,637 (22.9) |
26,548 (22.9) |
|
Sex | |||
F | 22,524 (77.7) | 90,096 (77.7) | 1.000 |
M |
6,473 (22.3) |
25,892 22.3) |
|
Concurrent conditions | |||
Cardiovascular disease | 8,100 (27.9) | 28,327 (24.4) | <0.0001 |
Diabetes mellitus | 2,480 (8.6) | 9,749 (8.4) | 0.419 |
Hyperlipidemia | 2,951 (10.2) | 8,301 (7.2) | <0.0001 |
Liver cirrhosis | 2,451 (8.5) | 7,277 (6.3) | <0.0001 |
COPD | 2,097 (7.2) | 8,247 (7.1) | 0.472 |
Chronic kidney disease | 270 (0.9) | 896 (0.8) | 0.007 |
HIV disease |
1 (0.003) |
9 (0.01) |
0.698 |
Charlson Comorbidity Index score§ | |||
0 | 12,653 (43.6) | 78,773 (67.9) | <0.0001 |
1 | 8,708 (30.0) | 20,791 (17.9) | |
2 | 4,381 (15.1) | 8,823 (7.6) | |
>3 |
3,255 (11.2) |
7,601 (6.6) |
|
Urbanization | |||
Urban | 17,167 (59.2) | 68,429 (59.0) | 0.668 |
Suburban | 4,098 (14.1) | 16,622 (14.3) | |
Rural | 7,732 (26.7) | 30,937 (26.7) |
*COPD, chronic obstructive pulmonary disease; RA, rheumatoid arthritis.
†Median, mean follow-up time for patients with RA = 5.1, 5.2 ± 3.1 y and for patients without RA = 11.0, 10.3 ± 2.1 y; p<0.0001.
‡Mean (± SD) age for patients with RA = 53.9 ± 14.1 y and for patients without RA = 53.5 ± 14.9 y; p<0.0001.
§Mean (± SD) index for patients with RA = 1.0 ± 1.3 and for patients without RA = 0.6 ± 1.2; p<0.0001.
1Deceased.
Page created: July 14, 2015
Page updated: July 14, 2015
Page reviewed: July 14, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.